Article
Aberrant BAF57 signaling facilitates prometastatic phenotypes.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2013
Balasubramaniam Sucharitha, Comstock Clay E S, Ertel Adam, Jeong Kwang Won, Stallcup Michael R, Addya Sankar, McCue Peter A, Ostrander William F, Augello Michael A, Knudsen Karen E
Abstract excerpt
PURPOSE: BAF57, a component of the switching-defective and sucrose nonfermenting (SWI/SNF) chromatin-remodeling complex conglomerate, modulates androgen receptor activity to promote prostate cancer. However, the molecular consequences of tumor-associated BAF57 expression have remained undefined in advanced disease such as castration-resistant prostate cancer and/or metastasis. EXPERIMENTAL DESIGN: Clinical human...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
